We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?
- Authors
Hsieh, Kety; Knöbl, Paul; Rintelen, Claudia; Kyrle, Paul A.; Quehenberger, Peter; Bialoczyk, Christine; Partsch, Hugo; Lechner, Klaus; Pabinger, Ingrid
- Abstract
Anti-beta2-glycoprotein I (beta2GPI) antibodies are frequently found in patients with lupus anticoagulant (LA). To investigate the prevalence of antibeta2GPI antibodies and their clinical impact in patients with a history of venous thromboembolism (VTE) without LA/anticardiolipin antibodies (ACA), we studied 503 patients [128 (36·2%) men, median age 41 years (interquartile range, IQR 28–54 years)] with previous thrombosis. A group of 113 individuals without VTE [43 (38·1%) men, age 46·7 years (IQR 38–52 years)] served as a control group. Among 418 patients without LA/ACA, anti-beta2GPI-IgG levels were elevated in seven (1·7%), -IgM in 15 (3·6%) and -IgA in 14 (3·3%) cases; in 58 patients with ACA, anti-beta2GPI-IgG levels were elevated in two (3·4%), six (10·3%) and three (5·2%), and in 27 with LA, they were elevated in 18 (66·7%), 19 (70·4%) and 10 (37%) respectively. Thus, the prevalence of elevated anti-beta2GPI antibodies was not increased in patients without LA/ACA but was strongly associated with LA. Patients without ACA/LA who had a recurrent event did not have higher prevalence of elevated anti-beta2GPI-IgG, -IgM or -IgA antibodies than those without a recurrent event. Thus, elevated antibeta2GPI antibodies are not likely to be a predictor of recurrent events in patients without LA. We conclude that determination of anti-beta2GPI antibodies does not improve the clinical management of patients with a history of VTE without LA/ACA.
- Subjects
HEMATOLOGY; BLOOD diseases
- Publication
British Journal of Haematology, 2003, Vol 123, Issue 3, p490
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1046/j.1365-2141.2003.04595.x